Literature DB >> 20553817

Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia.

J Wong1, T M Hyde, H L Cassano, A Deep-Soboslay, J E Kleinman, C Shannon Weickert.   

Abstract

The brain-derived neurotrophic factor (BDNF) gene contains multiple 5' promoters which generate alternate transcripts. Previously, we found that pan-BDNF mRNA and protein are reduced in the dorsolateral prefrontal cortex (DLPFC) from patients with schizophrenia. In this study, we determined which of the four most abundant and best characterized BDNF alternate transcripts, I-IX, II-IX, IV-IX, and VI-IX are altered in schizophrenia. Using a cohort from the NIMH, USA, we found that BDNF II-IX mRNA was significantly reduced in the DLPFC of patients with schizophrenia, and we replicated this finding using a second cohort from Sydney, Australia. Moreover, we show that BDNF protein expression [including prepro ( approximately 32 kDa), pro ( approximately 28 kDa) and mature ( approximately 14 kDa) BDNF] is reduced in the DLPFC of patients with schizophrenia. We next determined the regional specificity of the BDNF mRNA reduction by measuring BDNF transcripts in the parietal cortex and hippocampus and found no significant changes. The effect of antipsychotics on BDNF alternate transcript expression was also examined and we found no relationship between BDNF mRNA expression and antipsychotic use. As schizophrenic patients are often prescribed antidepressants which can up-regulate expression of BDNF, we investigated the relationship between antidepressant treatment and BDNF transcript expression. All four BDNF transcripts were significantly up-regulated in schizophrenic patients treated with antidepressants. Moreover, we found significant reductions in BDNF transcripts II-IX and IV-IX in the parietal cortex and VI-IX in the hippocampus of patients with schizophrenia who did not have a history of treatment with antidepressants. This suggests that down-regulation of at least one out of four major BDNF transcripts occurs in various brain regions of patients with schizophrenia, particularly in the DLPFC which appears to have the most robust BDNF deficit in schizophrenia. Copyright (c) 2010 IBRO. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553817      PMCID: PMC3118308          DOI: 10.1016/j.neuroscience.2010.05.037

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  70 in total

1.  BDNF and NT-4, but not NT-3, promote development of inhibitory synapses in the absence of neuronal activity.

Authors:  F J Seil
Journal:  Brain Res       Date:  1999-02-13       Impact factor: 3.252

2.  Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain.

Authors:  Lijun Zhou; Kai-Xing Huang; Alexsandar Kecojevic; Annie M Welsh; Vassilis E Koliatsos
Journal:  J Neurochem       Date:  2005-11-21       Impact factor: 5.372

3.  Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs.

Authors:  Ou Bai; Jennifer Chlan-Fourney; Rudy Bowen; David Keegan; Xin-Min Li
Journal:  J Neurosci Res       Date:  2003-01-01       Impact factor: 4.164

4.  Characterization of the responses of Purkinje cells to neurotrophin treatment.

Authors:  L Lärkfors; R M Lindsay; R F Alderson
Journal:  J Neurochem       Date:  1996-04       Impact factor: 5.372

Review 5.  Interaction between BDNF and serotonin: role in mood disorders.

Authors:  Keri Martinowich; Bai Lu
Journal:  Neuropsychopharmacology       Date:  2007-09-19       Impact factor: 7.853

6.  Exercise, antidepressant treatment, and BDNF mRNA expression in the aging brain.

Authors:  Antonio A Garza; Tony G Ha; Celithelma Garcia; Michael J Chen; Amelia A Russo-Neustadt
Journal:  Pharmacol Biochem Behav       Date:  2004-02       Impact factor: 3.533

7.  Effects of BDNF on dopaminergic, serotonergic, and GABAergic neurons in cultures of human fetal ventral mesencephalon.

Authors:  C Spenger; C Hyman; L Studer; M Egli; L Evtouchenko; C Jackson; A Dahl-Jørgensen; R M Lindsay; R W Seiler
Journal:  Exp Neurol       Date:  1995-05       Impact factor: 5.330

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Requirement for BDNF in activity-dependent survival of cortical neurons.

Authors:  A Ghosh; J Carnahan; M E Greenberg
Journal:  Science       Date:  1994-03-18       Impact factor: 47.728

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  39 in total

1.  Altered CREB Binding to Activity-Dependent Genes in Serine Racemase Deficient Mice, a Mouse Model of Schizophrenia.

Authors:  Darrick T Balu; Joseph T Coyle
Journal:  ACS Chem Neurosci       Date:  2017-11-27       Impact factor: 4.418

2.  Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder.

Authors:  Regina Taurines; Monica Segura; Martin Schecklmann; Laura Albantakis; Edna Grünblatt; Susanne Walitza; Thomas Jans; Benjamin Lyttwin; Michael Haberhausen; Frank M Theisen; Berthold Martin; Wolfgang Briegel; Johannes Thome; Christina Schwenck; Marcel Romanos; Manfred Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2014-02-06       Impact factor: 3.575

Review 3.  Neurodevelopment, GABA system dysfunction, and schizophrenia.

Authors:  Martin J Schmidt; Karoly Mirnics
Journal:  Neuropsychopharmacology       Date:  2014-04-24       Impact factor: 7.853

Review 4.  Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia.

Authors:  Farhana Islam; Benoit H Mulsant; Aristotle N Voineskos; Tarek K Rajji
Journal:  Curr Psychiatry Rep       Date:  2017-07       Impact factor: 5.285

5.  Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia.

Authors:  Sohei Kimoto; Jill R Glausier; Kenneth N Fish; David W Volk; H Holly Bazmi; Dominique Arion; Dibyadeep Datta; David A Lewis
Journal:  Schizophr Bull       Date:  2015-09-30       Impact factor: 9.306

Review 6.  Dopamine receptor homooligomers and heterooligomers in schizophrenia.

Authors:  Melissa L Perreault; Brian F O'Dowd; Susan R George
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 7.  Neurotrophin signalling: novel insights into mechanisms and pathophysiology.

Authors:  Mariela Mitre; Abigail Mariga; Moses V Chao
Journal:  Clin Sci (Lond)       Date:  2017-01-01       Impact factor: 6.124

8.  Working memory deficits, increased anxiety-like traits, and seizure susceptibility in BDNF overexpressing mice.

Authors:  Francesco Papaleo; Jill L Silverman; Jordan Aney; Qingjun Tian; Charlotte L Barkan; Kathryn K Chadman; Jacqueline N Crawley
Journal:  Learn Mem       Date:  2011-07-26       Impact factor: 2.460

9.  Increases in two truncated TrkB isoforms in the prefrontal cortex of people with schizophrenia.

Authors:  Jenny Wong; Debora A Rothmond; Maree J Webster; Cynthia Shannon Weickert
Journal:  Schizophr Bull       Date:  2011-07-27       Impact factor: 9.306

10.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.